James R. Tobin is Director at TransMedics Group, Inc. (TMDX). They have made 14 open-market trades across 3 companies since 2011, most recently 2026-08-17.
CIK 0001190128
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 14 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TMDX | SELL | 2024-08-08 | 2024-08-09 | $159.33 | $6.4M | +5.8% | -14.8% | -47.7% |
| TMDX | SELL · 10b5-1 | 2024-05-03 | 2024-05-07 | $125.05 | $3.0M | +9.3% | +5.4% | +17.6% |
| TMDX | SELL · 10b5-1 | 2024-05-01 | 2024-05-03 | $106.16 | $3.0M | +6.4% | +4.4% | +18.4% |
| TMDX | SELL · 10b5-1 | 2024-03-01 | 2024-03-05 | $83.62 | $2.2M | -9.4% | -7.9% | +59.4% |
| TMDX | SELL | 2023-11-28 | 2023-11-29 | $70.14 | $701K | -2.1% | +7.4% | +20.7% |
| TMDX | SELL | 2023-02-23 | 2023-02-27 | $75.13 | $751K | -0.9% | -5.6% | -7.3% |
| TMDX | SELL | 2022-07-29 | 2022-08-01 | $39.98 | $3.9M | +15.3% | +27.8% | +18.4% |
| TMDX | SELL | 2022-07-05 | 2022-07-06 | $35.00 | $1.7M | -3.9% | +45.6% | +33.9% |
| TMDX | SELL | 2022-05-04 | 2022-05-06 | $29.94 | $2.9M | +3.8% | +4.6% | +56.5% |
| GMED | SELL | 2022-03-15 | 2022-03-17 | $65.47 | $1.2M | +6.6% | +10.0% | -19.9% |
| GMED | SELL | 2022-03-08 | 2022-03-10 | $70.40 | $1.7M | -2.2% | +5.8% | -12.9% |
| GMED | SELL | 2021-05-10 | 2021-05-12 | $71.96 | $3.6M | +0.6% | +2.1% | +8.3% |
| TMDX | SELL | 2021-02-09 | 2021-02-10 | $32.81 | $661K | +11.5% | +9.6% | -29.3% |
| GMED | SELL | 2020-09-02 | 2020-09-03 | $56.85 | $318K | -6.3% | -13.0% | +4.1% |
| GMED | SELL | 2020-08-25 | 2020-08-26 | $54.40 | $947K | -0.0% | -10.6% | +8.8% |
| GMED | SELL | 2019-02-26 | 2019-02-28 | $47.59 | $1.8M | -6.0% | -1.2% | -19.1% |
| CRIS | SELL | 2011-03-30 | 2011-04-01 | $3.27 | $39K | -33.2% | -3.5% | -3.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.